Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis

Atherosclerosis

Volumn 146, Issue 2, 1999, Pages 249-257

  Keidar, Shlomo ^a   Attias, Judith ^a   Heinrich, Ronit ^a   Coleman, Raymond ^a   Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Angiotensin; Atherosclerosis; Cholesterol synthesis; HMG CoA reductase; Macrophage

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CHOLESTEROL; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOSARTAN; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LIPOPROTEIN DEFICIENCY; MACROPHAGE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CELL LINE; CHOLESTEROL; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INJECTIONS, INTRAPERITONEAL; MACROPHAGES, PERITONEAL; MICE; MONOCYTES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; VASOCONSTRICTOR AGENTS;

EID: 0032841861     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00145-8     Document Type: Article

References (29)

1. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis. 98:1993;1-9.
2. Aviram M., Fuhrman B. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol. Cell. Biochem. 188:1998;149-159.
3. Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur. J. Clin. Chem. Clin. Biochem. 34:1996;599-608.
4. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
5. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32:1997;405-425.
6. Keidar S. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci. 63:1998;1-11.
7. Daemen M.J., Lombardi D.M., Bosman F.T., Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. 68:1991;450-456.
8. Moore T.J., Taylor T., Williams G.H. Human platelet angiotensin II receptors: regulation by the circulating angiotensin level. J. Clin. Endocrinol. Metab. 58:1984;778-782.
9. Keidar S., Kaplan M., Hoffman A., Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis. 115:1995;201-215.
10. Keidar S., Kaplan M., Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler. Thromb. Vasc Biol. 16:1996;97-105.
11. Keidar S., Attias J. Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway. Biochem. Biophys. Res. Commun. 239:1997;63-67.
12. Chobanian A.V., Haudenschild C.C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanable heritable hyperlipidemic rabbit. Hypertension. 15:1990;327-331.
13. Aberg G., Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J. Cardiovasc. Pharmacol. 15 Suppl. 5:1990;S65-S72.
14. Charpiot P., Rolland P.H., Friggi A., Piquet P., Scalbert E., Bodard H., Barlatier A., Latrille V., Tranier P., Mercier C. et al. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler. Thromb. 13:1993;1125-1138.
15. Keidar S., Attias J., Smith J., Breslow J.L., Hayek T. The angiotensin II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun. 236:1997;622-625.
16. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. Apo E-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14:1994;133-140.
17. Reddick R.L., Zhang S.H., Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14:1994;141-147.
18. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Verstuyft J.D., Rubin E.M., Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1992;343-353.
19. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:1992;468-471.
20. Bancroft J.D., Cook H.C. Manual of Histological Techniques and their Diagnostic Applications. 1994;Churchill-Livingstone, Edinburgh, UK.
21. Shimono H., Horton J.D., Hammer R.E., Shimomura I., Brown M.S., Goldstein J.L. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98:1996;1575-1584.
22. Hayek T., Oiknine J., Brook J.G., Aviram M. Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem. Biophys. Res. Commun. 201:1994;1567-1574.
23. Leif S.J., Karin P., Gunnar A., Rolf G.G.A., Bengt E.K., Anders G.O. Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J. Cardiovasc. Pharmacol. 24:1994;670-677.
24. Masahiro S., Naoki M., Takashi Y. The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis. 127:1996;123-129.
25. Roth M., Emmons L.R., Perruchoud A., Block L.H. Expression of the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase genes are stimulated by recombinant platelet-derived growth factor isomers. Proc. Natl. Acad. Sci. USA. 88:1991;1888-1892.
26. Rudney H., Sexton R.C. Regulation of cholesterol biosynthesis. Annu. Rev. Nutr. 6:1986;245-272.
27. Schmitz U., Berk B.C. Angiotensin II signal transduction stimulation of multiple mitogen-activated protein kinase pathways. Trends. Endocrinol. Metab. 8:1997;261-266.
28. Teo K.K., Burton J.R., Buller C., Plante S., Yokoyama S., Montague T.J. Rationale and design features of a clinical trail examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: simvastatin/enalapril coronary atherosclerosis trial (SCAT). SCAT investigators. Can. J. Cardiol. 13:1997;591-599.
29. Hale L.P., Craver K.T., Berrier A.M., Sheffield M.V., Case L.D., Owen J. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler. Thromb. Vasc. Biol. 18:1998;1643-1646.